Methods of treating brain tumours and neuroblastomas
AssigneeAstraZeneca AB
InventorPetra HAMERLIK
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to methods of treating a brain tumour or a neuroblastoma in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a substituted azaquinolone compounds having activity as a poly(ADP-ribose) polymerase (PARP) inhibitor.
Claims33
1) A method of treating a brain tumour or a neuroblastoma in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a poly(ADP-ribose) polymerase (PARP) inhibitor,
- wherein the brain tumour or neuroblastoma comprises an alpha thalassemia/mental retardation syndrome X-linked (ATRX) deficient phenotype,
- wherein the PARP inhibitor is a compound of Formula I
- wherein:
- R1 is independently selected from H, C1-4 alkyl, C3-6 cycloalkyl, C1-4 fluoroalkyl, and C1-4 alkyloxy;
- R2 is independently selected from H, halo, C1-4 alkyl, and C1-4 fluoroalkyl;
- and
- R3 is H or C1-4 alkyl;
- R4 is halo or C1-4 alkyl,
- or a pharmaceutically acceptable salt thereof.
5) The method of any one of the preceding claims, further comprising a step of diagnosing the patient as having the brain tumour or neuroblastoma comprising the ATRX deficient phenotype prior to administering the PARP inhibitor.
8) The method of any one of the preceding claims, wherein the PARP inhibitor is administered to the patient in combination with
- i) an alkylating chemotherapeutic agent;
- and/or
- ii) ionizing radiation.
9) A method of treating a brain tumour or a neuroblastoma in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a poly(ADP-ribose) polymerase (PARP) inhibitor, and
- i) an alkylating chemotherapeutic agent;
- and/or
- ii) ionizing radiation administered at a dose of 10 Gy or above,
- wherein the PARP inhibitor is a compound of Formula I
- wherein:
- R1 is independently selected from H, C1-4 alkyl, C3-6 cycloalkyl, C1-4 fluoroalkyl, and C1-4 alkyloxy;
- R2 is independently selected from H, halo, C1-4 alkyl, and C1-4 fluoroalkyl;
- and
- R3 is H or C1-4 alkyl;
- R4 is halo or C1-4 alkyl,
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.